Genetic variants associated with Fabry disease progression despite enzyme replacement therapy.

about

Distinct Prognostic Values of Alcohol Dehydrogenase Family Members for Non-Small Cell Lung Cancer.

P2860

Q55225241-96D0F568-1DE1-431C-80C1-3E423FDDD6F3

P2860

Genetic variants associated with Fabry disease progression despite enzyme replacement therapy.

Item

http://www.wikidata.org/entity/Q47094778

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Genetic variants associated wi ...... te enzyme replacement therapy.

@en

Genetic variants associated wi ...... te enzyme replacement therapy.

@nl

type

Item

label

Genetic variants associated wi ...... te enzyme replacement therapy.

@en

Genetic variants associated wi ...... te enzyme replacement therapy.

@nl

prefLabel

Genetic variants associated wi ...... te enzyme replacement therapy.

@en

Genetic variants associated wi ...... te enzyme replacement therapy.

@nl

P1476

Genetic variants associated wi ...... te enzyme replacement therapy.

@en

P2093

Angela Nicoletti

http://www.w3.org/2001/XMLSchema#string

Daniela Concolino

http://www.w3.org/2001/XMLSchema#string

Eleonora Riccio

http://www.w3.org/2001/XMLSchema#string

Francesca Falvo

http://www.w3.org/2001/XMLSchema#string

Francesca Scionti

http://www.w3.org/2001/XMLSchema#string

Giuseppe Agapito

http://www.w3.org/2001/XMLSchema#string

Katia Roppa

http://www.w3.org/2001/XMLSchema#string

Licia Pensabene

http://www.w3.org/2001/XMLSchema#string

Mariamena Arbitrio

http://www.w3.org/2001/XMLSchema#string

Pietro Hiram Guzzi

http://www.w3.org/2001/XMLSchema#string

P2860

Long-term safety and efficacy of enzyme replacement therapy for Fabry disease

Cell death and diseases related to oxidative stress: 4-hydroxynonenal (HNE) in the balance

Regulation of the mammalian alcohol dehydrogenase genes

Time to treatment benefit for adult patients with Fabry disease receiving agalsidase β: data from the Fabry Registry.

Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data.

Home infusion program with enzyme replacement therapy for Fabry disease: The experience of a large Italian collaborative group

Xenobiotic-Metabolizing gene polymorphisms and ovarian cancer risk.

Fabry disease (alpha-galactosidase A deficiency): renal involvement and enzyme replacement therapy.

DMET-analyzer: automatic analysis of Affymetrix DMET data.

Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy

P304

107558-107564

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.22505

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Antonio Pisani

Maria Teresa Di Martino

P577

2017-11-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29296186

http://www.w3.org/2001/XMLSchema#string

P921

Enzyme replacement therapy

P932

5746088

http://www.w3.org/2001/XMLSchema#string

Genetic variants associated with Fabry disease progression despite enzyme replacement therapy.

about

P2860

P2860

Genetic variants associated with Fabry disease progression despite enzyme replacement therapy.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P932